Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077012 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
A Phase 1 study, sponsored by QLT.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00077012 is a Phase 1 study that has completed, run by QLT.
The verdict
NCT00077012, a Phase 1 study, has completed, sponsored by QLT.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1. To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign prostatic hyperplasia (BPH), evaluated by the American Urological Association Symptom Index (AUA SI), urinary flow rate (Qmax), and post-void residual volume (PVR). 2. To determine the extent of systemic exposure to QLT0074 following transurethral intraprostatic injection. 3. To select up to two transurethral PDT drug-light regimens for further clinical development.
Interventions
- DRUG QLT0074
- DRUG Photodynamic therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077012
The ClinicalTrials.gov registry entry for NCT00077012 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is QLT, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QLT0074 is the first listed.
NCT00077012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077012 about?
NCT00077012 is a clinical study titled "Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia". The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1. To determine if transurethral PDT with QLT0074 has a therapeutic effect on benign prostatic hyperplasia (BPH), evaluated by the American ...
What is the current status of trial NCT00077012?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00077012?
The interventions under investigation include: QLT0074 (DRUG), Photodynamic therapy (DRUG).
Who is sponsoring clinical trial NCT00077012?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.